Latest statistics indicate that Vietnam’s pharmaceutical industry is maintaining robust momentum, with a total market value reaching 8 billion USD annually. Notably, the sector’s compound annual growth rate (CAGR) stands at 8%, surpassing nations such as South Korea, Thailand, and Singapore to secure the second position in Asia, trailing only India.
Per capita pharmaceutical spending in Vietnam is projected to reach 78.3 USD by 2025. Currently, the supply structure is clearly diversified: high-value patented drugs are primarily imported from Europe and the United States, while products from South Korea and India dominate in terms of variety and pricing.
Regarding international supply capacity, Vietnam currently ranks 4th within ASEAN, with total exports valued at 312 million USD. Foreign-invested enterprises contribute 230 million USD to this figure, with the remainder generated by domestic entities.
Quality control efforts have also yielded positive results. Out of 40,000 tested samples, the rate of substandard products was only 0.6%, while counterfeit drugs remained extremely low at 0.024%. Simultaneously, the cosmetics market has seen significant demand, with Vietnam spending 1.27 billion USD on imports during the first ten months of 2025, mostly sourced from Southeast and Northeast Asia.